CPC A61K 35/74 (2013.01) [A61K 9/0053 (2013.01); A61K 9/0073 (2013.01); A61K 9/127 (2013.01); A61P 25/28 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); C12Q 1/689 (2013.01); C12Q 1/6886 (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); A61K 2039/6037 (2013.01)] | 6 Claims |
1. A method of reducing inflammation mediated by TNF-α or IL-6, comprising administering a composition comprising an effective amount of vesicles isolated from bacteria belonging to Proteus mirabilis to the subject having the inflammation.
|